Trials / Completed
CompletedNCT04330586
A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19
A Trial of Ciclesonide to Assess The Antiviral Effect for Adults With Mild-to-moderate COVID-19
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Korea University Guro Hospital · Academic / Other
- Sex
- All
- Age
- 19 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
According to In vitro studies, ciclesonide showed good antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although some cases were reported for the clinical effectiveness of ciclesonide in the treatment of COVID-19, there is no clinical trial to evaluate the antiviral effect on the reduction of viral load in patients with COVID-19. In this study, we aimed to investigate whether ciclesonide inhalation could eradicate SARS-CoV-2 compared to standard supportive care in patients with mild COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ciclesonide Metered Dose Inhaler [Alvesco] | Ciclesonide 320ug oral inhalation q12h for 14 days |
Timeline
- Start date
- 2020-04-01
- Primary completion
- 2021-03-31
- Completion
- 2021-03-31
- First posted
- 2020-04-01
- Last updated
- 2021-06-24
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04330586. Inclusion in this directory is not an endorsement.